BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37316442)

  • 21. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.
    Byeon S; Kim Y; Lim SW; Cho JH; Park S; Lee J; Sun JM; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2019 Apr; 51(2):623-631. PubMed ID: 30049203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
    Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
    Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
    Remon J; Hendriks LEL; Cardona AF; Besse B
    Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].
    Xu M; Luo J; Xu R
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):151-157. PubMed ID: 36872053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.
    Dorta-Suárez M; de Miguel M; Amor-Carro O; Calderón JM; González-Ortega M; Rodríguez-Abreu D
    Cancer Treat Rev; 2024 Mar; 124():102671. PubMed ID: 38281403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
    Piotrowska Z; Tan DS; Smit EF; Spira AI; Soo RA; Nguyen D; Lee VH; Yang JC; Velcheti V; Wrangle JM; Socinski MA; Koczywas M; Janik JE; Jones J; Yu HA
    J Clin Oncol; 2023 Sep; 41(26):4218-4225. PubMed ID: 37384848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
    Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients.
    Xu Y; Jia L; Zhang L; Wang H; Jiang L; Feng X; Wei R; Yao Q; Ren M; Xue T; Li Y; Zhu X; Zhou X; Bai Q
    Transl Lung Cancer Res; 2024 May; 13(5):986-997. PubMed ID: 38854943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.
    Liu B; Gao F; Zhao H; Yuan S; Peng X; Zhang P; Wang J; Zhang T; Duan M; Guo Y
    Eur J Med Chem; 2023 Oct; 258():115590. PubMed ID: 37406381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
    Girard N; Minchom A; Ou SI; Gadgeel SM; Trigo J; Viteri S; Bauml JM; Londhe A; Mahadevia P; Bazhenova L
    Clin Lung Cancer; 2022 Nov; 23(7):571-577. PubMed ID: 36085282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR exon 20 insertion mutations in non-small cell lung cancer.
    Wang F; Li C; Wu Q; Lu H
    Transl Cancer Res; 2020 Apr; 9(4):2982-2991. PubMed ID: 35117654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
    Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
    PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
    Brazel D; Kroening G; Nagasaka M
    BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs.
    Zhu N; Dong C; Weng S; Yuan Y; Yuan Y
    J Coll Physicians Surg Pak; 2019 Dec; 29(12):S126-S128. PubMed ID: 31779765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with
    Choudhury NJ; Schoenfeld AJ; Flynn J; Falcon CJ; Rizvi H; Rudin CM; Kris MG; Arcila ME; Heller G; Yu HA; Ladanyi M; Riely GJ
    Clin Cancer Res; 2021 May; 27(10):2920-2927. PubMed ID: 33685865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations].
    Yang WJ; Gao YB; Qiu T; Wang YG; He J
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):732-736. PubMed ID: 29061015
    [No Abstract]   [Full Text] [Related]  

  • 39. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
    Watanabe N; Horio Y; Fujiwara Y
    Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.